Pharma BD Deal Intelligence
Eli Lilly's acquisition of 4E Therapeutics adds a first-in-class oral MNK inhibitor, 4ET1103, to its non-opioid pain pipeline, following the SiteOne Therapeutics deal. Terms were undisclosed, and with the lead asset still in Phase 1, this is an early-stage bet whose payoff is years away.
Non-opioid pain bolt-on deepening Lilly neuroscience
Full analysis, sources & comparables →Lilly buys non-opioid pain drugmaker 4E; deal gives Lilly a pipeline of early-stage non-opioid therapeutics targeting the MNK-eIF4E signaling pathway.
Eli Lilly's M&A spree continues with acquisition of non-opioid pain drugmaker 4E; financial terms undisclosed.
4E Therapeutics, an Austin-based neuroscience company developing next-generation non-opioid treatments for chronic pain, announced it has been acquired by Eli…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
On June 16, 2026, Eli Lilly and Company announced the acquisition of 4E Therapeutics, an Austin, Texas-based neuroscience company developing non-opioid treatments for chronic pain. Financial terms were not disclosed. 4E's lead compound, 4ET1103, is an orally available MNK inhibitor targeting the MNK-eIF4E signaling pathway in peripheral sensory neurons; it is the first MNK inhibitor for pain to enter human trials and showed a favorable safety profile in a Phase 1 study. The deal adds to Lilly's non-opioid pain strategy, following its prior agreement to acquire sodium-channel-focused SiteOne Therapeutics, and marks one of Lilly's many 2026 acquisitions.
4E develops orally available MNK inhibitors that treat chronic pain by targeting the MNK-eIF4E signaling pathway in peripheral sensory neurons, aiming to deliver meaningful pain relief while avoiding the central-nervous-system effects associated with many existing analgesics. Lead 4ET1103 is the first MNK inhibitor for pain to reach human trials, with a favorable Phase 1 safety profile. Lilly acquired the company to expand its neuroscience/pain pipeline; financial terms were not disclosed.
Eli Lilly acquires Austin-based 4E Therapeutics to advance non-opioid chronic-pain treatments, adding oral MNK-inhibitor lead 4ET1103 and a backup pipeline. Financial terms were not disclosed.
Bolt-on acquisition of a Phase 1 non-opioid analgesic; deal value not disclosed, so financial magnitude is indeterminate.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / 4E Therapeutics, Inc. (this deal) | 2026 | — | 50 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2026 deals · Eli Lilly and Company deals · Neurology deals